'Assessing bioequivalence' presentation slideshows

Methods for Assessing Bioequivalence of Topical Products: How should FDA Redirect its Research Program?

Methods for Assessing Bioequivalence of Topical Products: How should FDA Redirect its Research Program?. Ajaz Hussain, Ph.D. Director (Act.), Office of Testing and Research OPS, CDER, FDA 17 November 2000. Bioavailability of Topical Drugs. Factors that effect bioavailability

687 views • 22 slides